Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS

PURPOSE: Blood eosinophil (EOS) count can guide treatment decisions for chronic obstructive pulmonary disease (COPD). In the 52-week ETHOS study (NCT02465567), budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) triple therapy at two inhaled corticosteroid doses reduced moderate/severe exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bafadhel, Mona, Rabe, Klaus F, Martinez, Fernando J, Singh, Dave, Darken, Patrick, Jenkins, Martin, Aurivillius, Magnus, Patel, Mehul, Dorinsky, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738173/
https://www.ncbi.nlm.nih.gov/pubmed/36510486
http://dx.doi.org/10.2147/COPD.S374670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738173/
https://www.ncbi.nlm.nih.gov/pubmed/36510486
http://dx.doi.org/10.2147/COPD.S374670

Ejemplares similares